Literature DB >> 17970969

Peyronie's disease (CME).

Anthony J Bella1, Michael A Perelman, William O Brant, Tom F Lue.   

Abstract

INTRODUCTION: The management of Peyronie's disease (PyD) presents several challenges to the clinician. Despite progress in the understanding of PyD on several fronts, it remains a physically and psychologically devastating condition for the affected patient and partner. AIM: The purpose of this Continuing Medical Education article is to review contemporary knowledge of the epidemiology, pathophysiology, evaluation, and management of PyD, thus enabling best-practice management.
METHODS: An English-language MEDLINE review was performed from 1990 to present-day for PyD. MAIN OUTCOME MEASURE: Current state of, and new developments in, PyD.
RESULTS: Recent studies have established a new paradigm for the natural history and epidemiology of PyD. Prevalence approaches 5%, while less than 20% of men report spontaneous resolution of deformity. The psychological sequelae on both patient and partner are underrepresented in literature; data gleaned from select Internet websites have better established Peyronie's effects on psyche and relationships. For the majority of patients, evaluation, information, and reassurance is sufficient. Few medical treatment options are supported by data from well-designed placebo-controlled trials. For men unresponsive to nonoperative therapies, plication, grafting, or implantation of a penile prosthesis are surgical management options.
CONCLUSIONS: PyD does not invariably progress to a complete loss of the ability for sexual intercourse. Should deformities preclude intercourse, well-established medical or surgical options may be considered; indeed, using one or more of the treatment approaches outlined can, in most cases, result in adequate restoration of sexual function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17970969     DOI: 10.1111/j.1743-6109.2007.00614.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  28 in total

1.  A novel approach for the surgical management of Peyronie's disease using an acellular, human dermis tissue graft: preliminary results.

Authors:  Ioannis Adamakis; Stavros I Tyritzis; Konstantinos G Stravodimos; Vasileios Migdalis; Dionysios Mitropoulos; Constantinos A Constantinides
Journal:  World J Urol       Date:  2010-10-06       Impact factor: 4.226

2.  Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix.

Authors:  Alan W Shindel; Guiting Lin; Hongxiu Ning; Lia Banie; Yun-Ching Huang; Gang Liu; Ching-Shwun Lin; Tom F Lue
Journal:  J Sex Med       Date:  2010-03-30       Impact factor: 3.802

3.  Efficacy of Collagenase Clostridium histolyticum (Xiapex®) in Patients with the Acute Phase of Peyronie's Disease.

Authors:  Andrea Cocci; Fabrizio Di Maida; Giorgio Ivan Russo; Paolo Capogrosso; Lotti Francesco; Michele Rizzo; Marina Di Mauro; Andrea Salonia; Gianmartin Cito; Marco Falcone; Andrea Romano; Gaia Polloni; Juan Ignacio Martinez-Salamanca; Esaù Fernández-Pascual; Andrea Minervini; Nicola Mondaini
Journal:  Clin Drug Investig       Date:  2020-06       Impact factor: 2.859

4.  Long-term results of the surgical treatment of Peyronie's disease with Egydio's technique: a European multicentre study.

Authors:  Salvatore Sansalone; Giulio Garaffa; Rados Djinovic; Stefano Pecoraro; Mauro Silvani; Guido Barbagli; Alessandro Zucchi; Giuseppe Vespasiani; Carla Loreto
Journal:  Asian J Androl       Date:  2011-07-11       Impact factor: 3.285

5.  A pilot study of penile hemodynamics in men with penile curvatures.

Authors:  A A Zaazaa; I Fathy; O Ayman; A Hassanin; H Ghanem
Journal:  Int J Impot Res       Date:  2017-01-12       Impact factor: 2.896

6.  Erectile preservation following radical prostatectomy.

Authors:  Robert Segal; Arthur L Burnett
Journal:  Ther Adv Urol       Date:  2011-02

Review 7.  Current status of the surgical management of Peyronie's disease.

Authors:  Ates Kadioglu; Faruk Küçükdurmaz; Oner Sanli
Journal:  Nat Rev Urol       Date:  2011-02       Impact factor: 14.432

8.  Evaluating the efficacy of intraplaque injection of dexamethasone with oral tadalafil in the chordee patients with Peyronie disease.

Authors:  Mohammad Hatampour; Karim Sohrabi; Hamid Mazdak; Keyvan Ghadimi; Hanieh Salehi; Reza Kazemi
Journal:  Am J Clin Exp Urol       Date:  2022-02-15

9.  Risk factors for emotional and relationship problems in Peyronie's disease.

Authors:  James F Smith; Thomas J Walsh; Simon L Conti; Paul Turek; Tom Lue
Journal:  J Sex Med       Date:  2008-07-14       Impact factor: 3.802

10.  Defining the impact of Peyronie's disease on the psychosocial status of gay men.

Authors:  Carolyn A Salter; Bruno Nascimento; Jean-Etienne Terrier; Hisanori Taniguchi; Helen Bernie; Eduardo Miranda; Lawrence Jenkins; Elizabeth Schofield; John P Mulhall
Journal:  Andrology       Date:  2020-10-10       Impact factor: 3.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.